Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.49 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.49 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638872 | 0.83 | EPHX2 (0.57) | EPHX1EPHX2TSHRKMT2A | |
| SCHEMBL3928986 | 0.81 | EPHX2 (0.61) | EPHX1EPHX2 | |
| SCHEMBL2638571 | 0.81 | EPHX2 (0.59) | EPHX1EPHX2TSHRMAPTKMT2A | |
| SCHEMBL14085442 | 0.77 | EPHX2 (0.68) | EPHX1EPHX2 | |
| SCHEMBL4542363 | 0.76 | EPHX1 (1.00) | EPHX1EPHX2LMNASMN1; SMN2MAPT | |
| SCHEMBL5160032 | 0.75 | EPHX1 (0.51) | EPHX1EPHX2TSHRKMT2A | |
| SCHEMBL4827562 | 0.75 | EPHX1 (0.51) | EPHX1EPHX2TSHRKMT2A | |
| SCHEMBL17437543 | 0.75 | EPHX1 (0.51) | EPHX1EPHX2TSHRKMT2A | |
| SCHEMBL29541898 | 0.75 | SLC6A1 (0.50) | EPHX1SLC6A1SLC6A11TSHRLMNA | |
| SCHEMBL29541932 | 0.74 | SLC6A1 (0.49) | EPHX1SLC6A1SLC6A11TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | EPHX1 810/4885EPHX2 2185/4885SLC6A1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.